Leptospirosis Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Leptospirosis Market Analysis
The leptospirosis market is projected to register a CAGR of 6.1% during the forecast period.
The COVID-19 pandemic severely impacted the leptospirosis market initially, with the temporary cancellation or delays in diagnosing and treating various non-COVID diseases, including leptospirosis infection. However, several countries reported growth in leptospirosis cases amid the outbreak. For instance, a study published in the Journal of Medical Virology in September 2022 stated that leptospirosis and coronavirus infection was endemic in the coastal regions of South India during the pandemic. Although, in the post-pandemic period, the cases of COVID-19 decreased, which led to the resumption of the leptospirosis treatment, which enabled the market to grow at the normal growth pace.
The leptospirosis market is expected to grow during the forecast period owing to the increase in the prevalence of leptospirosis and a surge in research and development activities for bacterial infections. For instance, a study published in Journal Pathogen in March 2022 stated that human leptospirosis infection is a leading and neglected source of morbidity and mortality, with more than 1 million cases and approximately 60,000 deaths per year. Further, a study published in the Journal Scientific Reports in January 2022 stated that a sampling of United States Virgin Islands (USVI) rodents determined that 45.7% (64/140) were carriers of pathogenic Leptospira species. The study stated that rodent exposure is associated with an increased risk of leptospirosis. The study also revealed that acute infections are more common in low-resource, tropical, and subtropical locations where outbreaks occur after natural disasters such as hurricanes, heavy rainfall, and flooding. With such a vast target population for leptospirosis infections, the market is likely to grow with higher demand for leptospirosis infection treatment in the coming years.
Furthermore, the activities in the research and developments for bacterial infections have increased, which is expected to boost the R&D of more leptospirosis treatment drugs and boost the market growth. For instance, in December 2021, a Research Project Grant from the Health Research Council of New Zealand (HRC) was awarded funding of NZD 1 million (USD 0.61 million) to Professor Jackie Benschop from the School of Veterinary Science. The research grant was awarded for the project "Enhancing leptospirosis diagnosis and outcomes for rural and Māori communities."
Therefore, the studied market is anticipated to grow over the analysis period due to the factors above, including the increasing prevalence of leptospirosis and the surge in research and development activities for bacterial infections. However, the lack of awareness about leptospirosis infections will likely impede market growth.
Leptospirosis Market Trends
Penicillin Segment is Expected to Witness a Significant Growth Over the Forecast Period
The penicillin segment is expected to register a significant growth rate throughout the forecast period owing to factors such as the surge in research and development and an increase in the prevalence of leptospirosis. Also, the advantages of penicillin treatment over other treatments and growing commercial availability promote the segment's growth during the forecast period.
Research studies have highlighted penicillin's efficacy in controlling leptospirosis infection, which is expected to increase awareness about the disease and elevate the adoption of penicillin for controlling leptospirosis infection and boost segment growth. For instance, a research study published in Membrane in March 2022 stated that early penicillin therapy had been efficient and could significantly reduce the risk of patients suffering from multiple organ failure caused by a leptospirosis infection. Furthermore, intravenous (IV) penicillin is advised for severe leptospirosis. Further, a study published in the journal Process Biology in February 2023 mentioned a penicillin-binding protein obtained from the structural and biochemical characterization of Leptospira interrogans Lsa45, which can be used to control the infection of Leptospira interrogans. Thus, such advancing studies underline the efficacy of penicillin and reveal more target penicillin-binding proteins for more effective management of leptospirosis infection. These factors are expected to attract more market growth opportunities by tapping the vast patient base of leptospirosis and treating the disease using penicillin which will boost the segment's growth during the forecast period.
Furthermore, the growing number of leptospirosis infections will likely positively impact the segment's growth. For instance, in July 2022, the southern district of Lindi, Tanzania, identified 20 cases of leptospirosis, a bacterial infection that has killed three people. Also, per the data published by the Australian Government Department of Health and Aged Care in April 2022, over 14 cases were reported in the Top End of the Northern Territory, Australia, in 2021.
Thus, with the high prevalence of leptospirosis and the advancing research, the segment is estimated to project substantial growth over the analysis period.
North America is Expected to Dominate the Leptospirosis Market Over the Forecast Period
North America is expected to hold a significant share of the leptospirosis market due to the surge in leptospirosis epidemics and growing awareness of bacterial infections. Also, the presence of drug manufacturers is expected to boost regional market growth. The region also has significant pets associated with zoonotic diseases of leptospirosis. This will increase the demand for leptospirosis diagnosis and treatment and expand the market's growth in the region. For instance, per the data published by the American Pet Products Association 2023-2024, over 66% of the households representing 86.9 million homes owned a pet in 2023 in the United States. Further, as per the data published by Pet Keen in May 2023, Canada has the highest percentage of pet owners among all the developed countries, with cats in over 38% of households and dogs in over 35% of households. Research studies have highlighted the risk of contracting leptospirosis infection from pet animals. For instance, a study published in the journal PLOS in January 2022 underlined the high burden of the zoonotic disease of Leptospira in humans from exposure to pis-hunting dogs in Queensland, Australia.
The significant burden of leptospirosis is expected to create a high demand for leptospirosis drugs to manage the infection effectively, likely boosting the market growth in the region. For instance, the data provided by the Centers for Disease Control and Prevention in 2022 stated that the United States had experienced leptospirosis outbreaks owing to floods in Hawaii, Florida, and Puerto Rico in 2021.
Research articles have underlined the significant burden of leptospirosis in the region, which is expected to create more awareness about the infection and boost the demand for leptospirosis infections drugs. For instance, an article published in STATPEARLS in May 2022 stated that zoonoses constitute 61% of infectious diseases and 75% of emerging ones. According to the same source, Leptospira is the most common zoonotic disease worldwide, and most cases in the United States are observed in Hawaii in farmers, veterinarians, and surfers. Therefore, owing to the factors above, the growth of the leptospirosis market is anticipated to be boosted in the North American region.
Furthermore, the healthcare bodies in the region have increased their focus to elevate the R&D of leptospirosis drugs to control the disease effectively, and it is likely to boost the growth of the regional market by supporting pipeline antibiotics. For instance, in December 2021, the Centers for Disease Control and Prevention (CDC) launched two global networks. They awarded USD 22 million to nearly 30 organizations worldwide to combat antimicrobial resistance and infectious diseases. Leptospirosis was one of the contagious diseases being considered.
Therefore, with the high burden of leptospirosis and increasing research funding, the studied market is anticipated to grow in the North America Region.
Leptospirosis Industry Overview
The leptospirosis market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The key players operating in the market include GlaxoSmithKline Plc, Novartis AG, AbbVie Inc, Cipla Inc, and Pfizer Inc.
Leptospirosis Market Leaders
-
GlaxoSmithKline Plc
-
Novartis AG
-
AbbVie Inc
-
Cipla Inc
-
Pfizer Inc
*Disclaimer: Major Players sorted in no particular order
Leptospirosis Market News
- In July 2022, Mylab Discovery Solutions launched 'PathoDetect Extended Monsoon Fever Panel,' which is a comprehensive multiplex RT PCR test kit for all monsoon diseases such as malaria, chikungunya, dengue, Zika, leptospirosis, and salmonellosis bacterial species, and Leishmaniasis parasites.
- In April 2022, the health ministry of Kerela state of India launched a campaign, 'Mrityunjayam,' to promote awareness about leptospirosis, as the monsoon season increases the risk of leptospirosis.
Leptospirosis Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increase in Prevalence of Leptospirosis
- 4.2.2 Surge in Research and Development Activities for Bacterial Infections
-
4.3 Market Restraints
- 4.3.1 Lack of Awareness about Leptospirosis Infections
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Treatment Type
- 5.1.1 Penicillin
- 5.1.2 Ampicillin
- 5.1.3 Doxycycline
- 5.1.4 Ceftriaxone
- 5.1.5 Azithromycin
- 5.1.6 Others
-
5.2 By Diagnosis
- 5.2.1 Microscopic Agglutination Test
- 5.2.2 Complete Blood Count
- 5.2.3 Urinalysis
- 5.2.4 Others (Blood Culture and Liver Enzymes, among others)
-
5.3 By End Users
- 5.3.1 Hospitals
- 5.3.2 Speciality Clinics
- 5.3.3 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.2 Europe
- 5.4.3 Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.5 South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 GlaxoSmithKline plc
- 6.1.2 Novartis AG
- 6.1.3 AbbVie Inc.
- 6.1.4 Cipla Inc.
- 6.1.5 Pfizer Inc.
- 6.1.6 Lupin Limited
- 6.1.7 Abbott Laboratories
- 6.1.8 Zydus Group
- 6.1.9 Aurobindo Pharma
- 6.1.10 Baxter International Inc.
- 6.1.11 Sun Pharmaceutical Industries Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityLeptospirosis Industry Segmentation
As per the scope of the report, leptospirosis is a zoonotic illness that can spread from animals to humans, and it can infect both people and animals. Leptospirosis can be acquired through the nose, mouth, eyes, or skin abrasions when a person encounters water that the infected animals have polluted. The Leptospirosis Market is Segmented by Treatment Type (Penicillin, Ampicillin, Doxycycline, Ceftriaxone, Azithromycin, Tetracycline, and Others), Diagnosis (Microscopic Agglutination Test, Complete Blood Count, Urinalysis, and Others), and End Users (Hospitals, Specialty Clinics, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for five different major regions globally.
| By Treatment Type | Penicillin |
| Ampicillin | |
| Doxycycline | |
| Ceftriaxone | |
| Azithromycin | |
| Others | |
| By Diagnosis | Microscopic Agglutination Test |
| Complete Blood Count | |
| Urinalysis | |
| Others (Blood Culture and Liver Enzymes, among others) | |
| By End Users | Hospitals |
| Speciality Clinics | |
| Other End Users | |
| Geography | North America |
| Europe | |
| Asia-Pacific | |
| Middle East and Africa | |
| South America |
Leptospirosis Market Research FAQs
What is the current Global Leptospirosis Market size?
The Global Leptospirosis Market is projected to register a CAGR of 6.10% during the forecast period (2024-2029)
Who are the key players in Global Leptospirosis Market?
GlaxoSmithKline Plc, Novartis AG, AbbVie Inc, Cipla Inc and Pfizer Inc are the major companies operating in the Global Leptospirosis Market.
Which is the fastest growing region in Global Leptospirosis Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Leptospirosis Market?
In 2024, the North America accounts for the largest market share in Global Leptospirosis Market.
What years does this Global Leptospirosis Market cover?
The report covers the Global Leptospirosis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Leptospirosis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Leptospirosis Industry Report
Statistics for the 2024 Leptospirosis market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Leptospirosis analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
